Royalty Report: Drugs, Disease, Biotechnology – Collection: 5085


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Disease
  • Biotechnology
  • Diagnostic Substances
  • Diagnostic
  • Therapeutic
  • Cancer
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5085

License Grant
The Company obtained from the Canadian University the exclusive, worldwide license (the Tyrosine Kinase License), with the right to grant sublicenses, to make, use and sell an invention relating to early diagnosis of seronegative HIV infection using Tyrosine Kinase Activity described in the inventions claimed in certain Canadian and United States patent applications (collectively, the Licensed Tyrosine Kinase Technology).
License Property
HIV infections are usually diagnosed by measuring antibodies produced in response to the infection.  Two important issues in managing HIV infections are the lag time between infection and production of antibodies, and the inability to use antibody response to track the viral load of the infection.  At present, viral load is measured to monitor the effectiveness of therapies for HIV by nucleic acid assays which are complex and costly.  Although no assurance can be given, a new assay method using the Licensed Tyrosine Kinase Technology, which does not rely on antibody or nucleic acid markers, may find application in a number of areas for the management of HIV therapies.
Field of Use
The rights granted are relating to early diagnosis of seronegative HIV infection.

IPSCIO Record ID: 27049

License Grant
SDRCC hereby grants to the Canadian Company, subject to the terms and conditions of this Agreement, an exclusive license to use and sublicense the Technology, and to make or have made Licensed Products, in the Territory and to market, distribute, and sell Licensed Products worldwide.
License Property
The technology, generally characterized as Antibody IFT’ and described in U.S. Patent Application Number 07/848,327 entitled an anti-idiotypic antibody and its use in diagnosis and therapy in HIV related disease.
Field of Use
The rights granted apply in the healthcare industry.

IPSCIO Record ID: 26501

License Grant
The Canadian Licensor hereby grants to Licensee a worldwide, exclusive license and sublicense (including the right to grant sublicenses) in the Field under the Licensed IP Rights to research, develop, make, have made, use, offer for sale, sell and import Licensed Products, and practice Licensed Methods, in each case for the detection and/or measurement of PCA3(DD3) as a marker for the diagnosis monitoring, prognosis, or drug susceptibility of prostate cancer.
License Property
The Licensor owns or has intellectual property rights with respect to the PCA3(DD3) gene (as defined below) and certain related technology.

APTIMA(R) Technology shall mean all technology reasonably necessary to make or use Licensee's APTIMA generation of amplified nucleic acid assays, including Target Capture (TC), Transcription-Mediated Amplification (TMA), Hybridization Protection Assay (HPA) and Dual Kinetic Assay (DKA) technologies, each to the extent in each case that Licensee has a right to license or sublicense.

The technology is a diagnostic technology (genetic) for the early warning of prostate cancer.

The licensor's (Quebec, Canada) urine test (PCA3) to detect the genetic marker of prostate cancer is now being developed by the licensee based in San Diego, and after more clinical trials a new version will hit the market by year end (2005).

Field of Use
Field shall mean the detection and/or measurement of PCA3(DD3) as (a) a marker for the diagnosis, monitoring, prognosis, or drug susceptibility of prostate cancer; and/or (b) a marker for cancer (without limitation).  The Field shall not include the use of any assay in drug discovery.

IPSCIO Record ID: 4321

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts a non-exclusive, royalty-bearing license during the Term, under the Inverness Lateral Flow Patents, to manufacture and to Exploit the HIV Cassette Products in the Rest of the World.
License Property
Licensor, among other activities, is in the business of developing, marketing and selling products used to diagnose various diseases, including HIV, and owns or has rights to grant licenses to a number of patents pertaining to HIV diagnosis, including the Licensor's Lateral Flow Patents. Licensor asserts that the HIV Cassette Product is within the scope of the claims of the Licensor's Lateral Flow Patents.

HIV Cassette Product means the Licensee product currently known as HIV 1/2 STAT PAK(TM) as described in Licensee's PMA on file with the FDA and further described in the HIV 1/2 STAT PAK(TM) package insert, Catalog #HIV 102, together with any improvements thereto.

Field of Use
Visual-Read HIV Test shall mean a rapid, non-digital diagnostic test for antibodies to HIV designed primarily to be read by the naked eye and to be used in a Point of Care environment. A Visual-Read HIV Test expressly excludes digital tests that include a reading device or integrated digital technology to aid in the interpretation or indication of the result.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.